|
Session 120
Poster Abstracts
Immune-Based Therapies: Cytokines
Wednesday, 1-4 pm
Room: Hall A |
702
 |
Predictors of Slow Disease Progression in ART-naive HIV-1-infected Patients Treated with IL-2: 3 Year Extended Follow-up of the Interstart ANRS 119 Trial
Jean-Michel Molina*1, Y Levy2, I Fournier3, T Boulet3, M Bentata4, G Beck-Wirth5, D Sereni1, F Jeanblanc6, F Simon1, J P Aboulker3, and the ANRS 119-Interstart study team
1Hosp St Louis, Paris, France; 2Hosp Henri Mondor, Creteil, France; 3INSERM SC10, Villejuif, France; 4Hosp Avicenne, Bobigny, France; 5Hosp Emile Muller, Mulhouse, France; and 6Hosp Edouard Herriot, Lyon, France |
703
|
Immunological Success Is Predicted by Enfuvirtide but Not Interleukin-2 in Immunocompromised Patients, Final Results of the ANRS 123 ETOILE Randomized Trial
Jean-Paul Viard*1, C Fagard2, C Rouzioux1, E Pereira2, M Bentata3,4,5, N Colin de Verdiere4, G Pahlavan5, L Weiss6, Y Levy7, G Chene2, and The ANRS 123 Study Group
1Ctr Hosp Univ Necker, Paris, France; 2INSERM U593, Bordeaux, France; 3Ctr Hosp Univ Avicenne, Bobigny, France; 4Ctr Hosp Univ St Louis, Paris, France; 5Ctr Hosp Univ Bichat, Paris, France; 6Ctr Hosp Univ Georges Pompidou, Paris, France; and 7Ctr Hosp Univ Henri-Mondor, Creteil, France |
704
|
CD4 T Cell Survival following Intermittent IL-2 Therapy Is Predictive of CD4 T Cell Increases in HIV-infected Patients
Sarah Read*1, R Lempicki2, M Di Mascio1, S Srinivasula1,2, I Sereti1, R Davey1, J Tavel1, C Y Huang1, C Lane1, and J Kovacs3
1NIAID, NIH, Bethesda, MD, US; 2SAIC-Frederick, MD, US; and 3Warren G Magnuson Clinical Ctr, NIH, Bethesda, MD, US |
705
|
Response to IL-2 in Patients with Immunodiscordant Response to HAART Is Associated with Long-term Clinical Benefit
Matilde Sanchez-Conde*, J Lopez, C Rodriguez, M Ramirez, I Gutierrez, J Cosin, J Berenguer, and P Miralles
Hosp Gregorio Maranon, Madrid, Spain |
706
|
During HAART Interruption Interleukin-2 Was Ineffective in Maintaining Baseline CD4 T Cell Counts in IL-2-experienced Recipients: Results of a Randomized, Controlled Trial
Brian Porter*1, K Anthony2, J Shen1, B Hahn1, B Blackwelder1, C Lane1, J Kovacs1, R Davey1, and I Sereti1
1NIH, Bethesda, MD, US and 2Univ of Pennsylvania Hlth System, Philadelphia, US |
| 707 |
IL-7 Immunotherapy and T Cell Homeostasis in SIV+ ART-treated Macaques
Amanda Leone*1, M Rohankedkhar2, A Okoye2, B Assouline3, M Morre3, F Villinger4, L Picker2, and D Sodora1
1Seattle Biomed Res Inst, Seattle, US; 2Vaccine and Gene Therapy Inst and Oregon Natl Primate Res Ctr, Oregon Hlth and Sci Univ, Beaverton, US; 3Cytheris SA, Issy les Moulineaux, France; and 4Emory Univ, Atlanta, GA, US |
| 708 |
Sustained Immunological Efficacy of Repeated r-hIL-7 Doses in HIV-1-infected Patients. Long-term Follow-up of a Phase I/II Multicenter Study
Yves Levy*1,2, L Weiss2,3,4, C Goujard5, J P Viard6, J M Molina7, F Boue8, C Lacabaratz2, C Rouzioux6, M Morre9, and J F Delfraissy6
1Henri Mondor Hosp, Creteil, France; 2INSERM, Creteil, France; 3Hosp Georges Pompidou, Paris, France; 4Univ Rene Descartes, Paris, France; 5Hosp Bicetre, Le Kremlin Bicetre, France; 6Ctr Hosp Univ Necker, Paris, France; 7St Louis Hosp, Paris, France; 8Hosp Antoine Beclere, Clamart, France; and 9Cytheris, France |
| 709 |
Early T Cell Homing following Recombinant Simian Glycosylated IL-7 Injection in Rhesus Macaques
S Beq1, S Rozlan2, D Gautier1, B Assouline2, P Lavedan1, Michel Morre*2, and R Cheynier1
1Pasteur Inst, Paris, France and 2Cytheris SA, Issy les Moulineaux, France |
710
|
Morpholino Antisense Oligomers Targeting Human IL-10 Pre-mRNA Splice Sites Modulate IL-10 Secretion by Human Dendritic Cells
Richard Bestwick*1, D Mourich1, N Marshall1, M Lubkin1, S Oda1, S Thompson2, K Warfield3, S Bavari3, and P Iversen1
1AVI BioPharma Inc, Corvallis, OR, US; 2Oregon Hlth Sci Univ, Portland, US; and 3USAMRIID, Fort Detrick, Frederick, MD, US |
711
|
Interleukin-27, a Novel Anti-HIV Cytokine, Inhibits HIV-1 Replication in Macrophages with the Activation of Multiple Interferon-inducible Genes
Terrence Brann*1, J Yang1, D W Huang1, B Fullmer1, J Adelsberger1, R Lempicki1, M Baseler1, C Lane2, and T Imamichi1
1SAIC-Frederick, MD, US and 2NIAID, NIH, Bethesda, MD, US |
|
